Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 2/20 | 0.48 |
| ▸ | OAT | P04181 | 1/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083101 | 1.00 | ABAT (0.48) | ABATOATGABRR1MAPTPOLB | |
| SCHEMBL301495 | 0.88 | — | — | |
| SCHEMBL28490005 | 0.86 | — | — | |
| Benzene SCHEMBL27796799 | 0.83 | AKR1C3 (0.43) | ABATGABRR1MAPTPOLBCYP2C19 | |
| SCHEMBL1650296 | 0.83 | BRD4 (0.44) | ABATOATMAPTCYP1A2KMT2A | |
| SCHEMBL15106137 | 0.79 | ABAT (0.41) | ABATOATGABRR1MAPTPOLB | |
| SCHEMBL15116653 | 0.79 | ABAT (0.41) | ABATOATGABRR1MAPTPOLB | |
| SCHEMBL1839380 | 0.78 | MAPT (0.44) | ABATMAPTPOLBCYP2C19CYP1A2 | |
| SCHEMBL21783791 | 0.78 | ABAT (0.34) | ABATOATMAPT | |
| SCHEMBL23366184 | 0.75 | CYP2C19 (0.50) | ABATGABRR1CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11415887-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-08-16 | — | — | US | disclosed |
| US-20210302838-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20200272048-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200241414-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-7897611-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1858857-B1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | LILLY CO ELI (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1678172-B1 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-23 | — | — | US | disclosed |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | TARGACEPT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7402592-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1858857-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006096358-A1 | AZABICYCLOALKANE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-14 | — | — | WO | disclosed |
| EP-1678172-A2 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037832-A9 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | — | 2006-01-26 | — | — | WO | disclosed |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005037832-A2 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | OPRL1, OPRK1, COMT | ABAT 874/4885OAT 1259/4885GABRR1 235/4885 |
| US-20080261999-A1 | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists | CHRNA1, CHRNA7, CHRNB1 | ABAT 1776/4885OAT 3657/4885GABRR1 199/4885 |
| US-20200241414-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | INSR, HNRNPU, HNRNPR | ABAT 3326/4885OAT 2983/4885GABRR1 1538/4885 |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | ABAT 874/4885OAT 1259/4885GABRR1 235/4885 |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | ABAT 874/4885OAT 1259/4885GABRR1 235/4885 |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | ABAT 874/4885OAT 1259/4885GABRR1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.